Advertisement

Pain pp 311-314 | Cite as

Ziconotide Intrathecal Therapy

  • Samita S. Das
  • Salim M. HayekEmail author
Chapter

Abstract

Ziconotide is a non-opioid, potent intrathecal analgesic with mechanism of action involving interruption of spinal neurotransmission approved by the Food and Drug Administration in 2004 for the treatment of severe refractory chronic pain. Presented are pertinent diagnoses and proper patient selection for ziconotide therapy, guidelines for treatment, and current evidence for analgesic efficacy and safety for intrathecal use.

Keywords

Ziconotide Intrathecal analgesia N-type calcium channel blocker 

References

  1. 1.
    McGivern JG. Ziconotide: a review of its pharmacology and use in the treatment of pain. Neuropsychiatr Dis Treat. 2007;3(1):69–85.CrossRefGoogle Scholar
  2. 2.
    Staats PS, Yearwood T, Charapata SG, Presley RW, Wallace MS, Byas-Smith M, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA. 2004;291(1):63–70.CrossRefGoogle Scholar
  3. 3.
    Wallace MS, Charapata SG, Fisher R, Byas-Smith M, Staats PS, Mayo M, et al. Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial. Neuromodulation. 2006;9(2):75–86.CrossRefGoogle Scholar
  4. 4.
    Rauck RL, Wallace MS, Leong MS, Minehart M, Webster LR, Charapata SG, et al. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manag. 2006;31(5):393–406.CrossRefGoogle Scholar
  5. 5.
    Ver Donck A, Collins R, Rauck RL, Nitescu P. An open-label, multicenter study of the safety and efficacy of intrathecal ziconotide for severe chronic pain when delivered via an external pump. Neuromodulation. 2008;11(2):103–11.CrossRefGoogle Scholar
  6. 6.
    Wermeling D, Drass M, Ellis D, Mayo M, McGuire D, O’Connell D, et al. Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients. J Clin Pharmacol. 2003;43(6):624–36.Google Scholar
  7. 7.
    Mohammed SI, Eldabe S, Simpson KH, Brookes M, Madzinga G, Gulve A, Baranidharan G, Radford H, Crowther T, Buchser E, Perruchoud C, Batterham AM. Bolus intrathecal injection of ziconotide to evaluate the option of continuous administration via an implanted intrathecal drug delivery system: a pilot study. Neuromodulation. 2013;16:576–82.CrossRefGoogle Scholar
  8. 8.
    Deer T, Rauck RL, Kim P, Saulino M, Wallace M, Grigsby E, Huang I, Mori F, Vanhove G, McDowell G II. Effectiveness and safety of intrathecal ziconotide: interim analysis of the Patient Registry of Intrathecal Ziconotide Management (PRIZM). Pain Pract. 2018;18(2):230–8.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Anesthesiology: Division of Pain MedicineUniversity Hospitals Cleveland Medical CenterClevelandUSA

Personalised recommendations